Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sophia Genetics SA (SOPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: SOPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7
1 Year Target Price $7
| 4 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.25% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 218.28M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 6 | Beta 1.02 | 52 Weeks Range 2.58 - 4.92 | Updated Date 09/17/2025 |
52 Weeks Range 2.58 - 4.92 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -105.32% | Operating Margin (TTM) -100.92% |
Management Effectiveness
Return on Assets (TTM) -23.46% | Return on Equity (TTM) -74.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 187272978 | Price to Sales(TTM) 3.13 |
Enterprise Value 187272978 | Price to Sales(TTM) 3.13 | ||
Enterprise Value to Revenue 2.69 | Enterprise Value to EBITDA -0.3 | Shares Outstanding 67579600 | Shares Floating 50710350 |
Shares Outstanding 67579600 | Shares Floating 50710350 | ||
Percent Insiders 6.46 | Percent Institutions 48.2 |
Upturn AI SWOT
Sophia Genetics SA
Company Overview
History and Background
Sophia Genetics SA was founded in 2011 in Switzerland. The company developed an AI-powered platform for data-driven medicine, initially focusing on genomic analysis and expanding to broader healthcare data applications.
Core Business Areas
- Data Analytics Platform: The SOPHiA DDM platform analyzes complex genomic and clinical data to aid in diagnostics and treatment decisions.
- Clinical Genomics Solutions: Provides solutions for various clinical applications, including oncology, inherited disorders, and infectious diseases.
- Data Sharing and Collaboration: Facilitates data sharing among healthcare providers and researchers to improve patient outcomes.
Leadership and Structure
The company is led by a CEO and a management team with expertise in genomics, data science, and healthcare. The organizational structure is designed to support product development, commercialization, and partnerships.
Top Products and Market Share
Key Offerings
- SOPHiA DDM Platform: The company's core platform for genomic and clinical data analysis. Competitors include Illumina (ILMN), Thermo Fisher Scientific (TMO), and Qiagen (QGEN). Market share data is not readily available due to the fragmented nature of the market. Significant portion of revenue.
- Oncology Solutions: Specific analytical solutions for oncology, including tumor profiling and minimal residual disease monitoring. Competitors include Foundation Medicine (part of Roche), Guardant Health (GH), and Exact Sciences (EXAS). Market share data is not readily available due to the fragmented nature of the market. Significant portion of revenue.
Market Dynamics
Industry Overview
The genomic analysis and precision medicine market is experiencing rapid growth, driven by advancements in sequencing technologies, increasing adoption of personalized medicine, and growing demand for data-driven healthcare solutions.
Positioning
Sophia Genetics positions itself as a leader in data-driven medicine, offering a comprehensive platform for genomic and clinical data analysis. Its competitive advantages include its AI-powered platform, its extensive database of genomic information, and its partnerships with leading healthcare institutions.
Total Addressable Market (TAM)
The total addressable market for data-driven medicine is estimated to be in the billions of dollars. Sophia Genetics is positioned to capture a significant share of this market through its innovative platform and strategic partnerships.
Upturn SWOT Analysis
Strengths
- AI-powered data analytics platform
- Extensive genomic database
- Strong partnerships with healthcare institutions
- Comprehensive solutions for various clinical applications
- Global presence
Weaknesses
- Reliance on partnerships for data acquisition
- Limited brand recognition compared to larger competitors
- Competition from established players with deeper pockets
- Negative profit margin in recent times
Opportunities
- Expanding adoption of precision medicine
- Increasing demand for data-driven healthcare solutions
- Growing market for genomic analysis in emerging markets
- Potential for strategic acquisitions and partnerships
- Expansion into new clinical applications
Threats
- Competition from established players
- Regulatory hurdles for genomic analysis
- Data privacy and security concerns
- Pricing pressure from healthcare providers
- Rapid technological advancements
Competitors and Market Share
Key Competitors
- ILMN
- TMO
- QGEN
- GH
- EXAS
Competitive Landscape
Sophia Genetics differentiates itself through its AI-powered platform, while larger competitors have broader product portfolios and greater market reach. Partnerships are key to staying competitive.
Growth Trajectory and Initiatives
Historical Growth: Historical growth rates have been characterized by revenue growth, but also by increasing operational expenditure, which can vary annually.
Future Projections: Future projections are largely based on analyst estimates, indicating continued revenue growth and potential movement towards profitability. Investors should consider those estimates as predictions only.
Recent Initiatives: Recent initiatives include expansion of product offerings, strategic partnerships, and geographical expansion.
Summary
Sophia Genetics operates in a high-growth sector, leveraging its AI platform to analyze genomic data. While the company has forged strategic partnerships, it faces stiff competition from larger, established players. Financial performance reveals ongoing revenue growth but concerns about profitability. Investors should consider the stock high risk but with a high reward profile.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Third-party data providers
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary depending on the source. The AI-based rating is based on available data and may not reflect all relevant factors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sophia Genetics SA
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-23 | Co-Founder, CEO & Director Dr. Jurgi Camblong M.B.A., Ph.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 423 | Website https://www.sophiagenetics.com |
Full time employees 423 | Website https://www.sophiagenetics.com | ||
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is based in Rolle, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.